Correlation of Antiphospholipid Antibody Recognition with the Structure of Synthetic Oxidized Phospholipids.

Author(s): Friedman P, Horkko S, Steinberg D, Witztum JL, Dennis EA

Abstract

The oxidation of low density lipoproteins (LDL) has been correlated with atherogenesis through a variety of pathways. The process involves nonspecific fragmentation, oxidative breakdown, and modification of the lipids and protein of LDL. The process yields a variety of bioactive products, including aldehyde-containing phospholipids, which can cross-react with primary amines (i.e. peptides or phospholipid head groups) to yield Schiff base products. We also demonstrate that such oxidized phospholipid products may further react through a post-oxidation chemical pathway involving aldol condensation. EO6, an IgM monoclonal autoantibody to oxidized phospholipids, blocks the uptake of oxidized LDL (OxLDL) by macrophages. Because the epitope(s) of EO6 also blocks the uptake of OxLDL, a series of oxidized phospholipids, their peptide complexes, and their aldol condensates have been synthesized and characterized, and their antigenicity has been determined. This study defines structural motifs of oxidized phospholipids responsible for antigenicity for EO6. Certain monomeric phospholipids containing short chain fatty acids were antigenic whether oxidized or not in the sn-2 position. However, oxidized phospholipids containing sn-1 long chain fatty acids were not antigenic unless the sn-2 oxidized fatty acid contained an aldehyde that first reacted with a peptide yielding a Schiff base or the sn-2 oxidized fatty acid underwent an aldol type self-condensation. Our data indicate that the phosphorylcholine head group is essential for antigenicity, but its availability depends on the oxidized phospholipid conformation. We suggest that upon oxidation, similar reactions occur in phospholipids on the surface of LDL, generating ligands for macrophage recognition. Synthetic imine adducts of oxidized phospholipids of this type are capable of blocking the uptake of OxLDL.

Similar Articles

Global Atlas on Cardiovascular Disease Prevention and Control.

Author(s): Mendis S, Puska P, Norrving B

Pathogenesis of Acute Coronary Syndromes

Author(s): Crea F, Liuzzo G

Mechanisms of Plaque Formation and Rupture

Author(s): Bentzon JF, Otsuka F, Virmani R, Falk E

Matrix Metalloproteinase-9?: Many Shades of Function in Cardiovascular Disease.

Author(s): Yabluchanskiy A, Ma Y, Iyer RP, Hall ME, Lindsey ML

Association of serum MMP-9 with autoantibodies against oxidized LDL

Author(s): Kalela A, Koivu TA, Höyhtyä M, Jaakkola O, Lehtimäki T

2013 ESC guidelines on the management of stable coronary artery disease: Eur Heart

Author(s): Montalescot G, Sechtem U, Achenbach S, Andreotti F

Chronic Stable Angina.

Author(s): Abrams J

The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease.

Author(s): Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A

The oxidation ratio of LDL: a predictor for coronary artery disease.

Author(s): Huang H, Mai W, Liu D, Hao Y, Tao J

Antibodies against oxLDL and acute coronary syndrome.

Author(s): Medeiros AM, von Mühlen CA, Gidlund MA, Bodanese R, Gottlieb MG

Plaque regression and plaque stabilisation in cardiovascular diseases.

Author(s): Dave T, Ezhilan J, Vasnawala H, Somani V

Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease

Author(s): Kalela A, Koivu TA, Sisto T, Kanervisto J, Höyhtyä M